Comment on

• Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.

  Schnipper LE, Davidson NE, Wollins DS, Blayney DW, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Vose JM, Schilsky RL. Schnipper LE, et al. J Clin Oncol. 2016 Aug 20;34(24):2925-34. doi: 10.1200/JCO.2016.68.2518. Epub 2016 May 31. J Clin Oncol. 2016. PMID: 27247218 No abstract available.
• Relevance of American Society of Clinical Oncology Value Framework Will Be Improved if It Is Based on Network Meta-Analyses.

  Jansen JP. Jansen JP. J Clin Oncol. 2017 Apr 1;35(10):1131-1132. doi: 10.1200/JCO.2016.69.4612. Epub 2017 Feb 6. J Clin Oncol. 2017. PMID: 28165901 No abstract available.
• Appraisal of Innovative Anticancer Agents: Do the Scores of European Society for Medical Oncology-Magnitude of Clinical Benefit Scale and American Society of Clinical Oncology Task Force Correlate With Survival Gains?

  Messori A, Trippoli S, Marinai C. Messori A, et al. J Clin Oncol. 2017 Apr 1;35(10):1132-1133. doi: 10.1200/JCO.2016.69.2731. Epub 2017 Feb 6. J Clin Oncol. 2017. PMID: 28165906 No abstract available.
• American Society of Clinical Oncology Value Framework: Importance of Accurate Toxicity Data.

  Jim HS, McLeod HL. Jim HS, et al. J Clin Oncol. 2017 Apr 1;35(10):1133-1134. doi: 10.1200/JCO.2016.69.2079. Epub 2017 Feb 6. J Clin Oncol. 2017. PMID: 28165908 No abstract available.